Title: Lonza
Signs Deal with LegoChem Biosciences to Provide Pre-clinical Material of
Therapeutic Compound Publication: IHS Chemical Week Date: 8 Mar 2012 URL: link
to website
Summary
Lonza says it has signed an agreement
with biotech company LegoChem Biosciences (Daejeon, Korea), for the custom
material production of a monoclonal antibody that will be used for in vivo
proof of concept studies for their technology platform development. About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a
research-based biotechnology company dedicated to discovering, developing, and
commercializing innovative medicines by leveraging our chemistry expertise to
make conventional biologics targeted and more potent for the benefit of
patients with diseases of high unmet medical needs. We are advancing
sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants,
oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).
|
|
IP : 106.243.208.*** 
|
